Saturday 17 October 2026
Export CLVSQ’s income statement to Excel — free account
Clovis Oncology, Inc.
CLVSQ Healthcare Biotechnology
Operating cash flow growth for five consecutive years.
Follow CLVSQ
| Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 2 | 3 | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.10 | 2.46 | 3.93 | 9.80 | 55.98 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(22.42) | (16.27) | (12.63) | (5.95) | (2.81) | (13.15) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
(3.14) | (3.08) | (2.49) | (1.20) | 629.87 | — |
P/Operating CF |
(7.57) | (7.22) | (8.01) | (11.30) | (47.39) | (30.23) |
P/B ratio |
0.00 | 0.00 | 0.00 | 6.38 | 8.45 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 29.72 | 10.99 | 0.00 |
EV/Sales |
5.30 | 4.71 | 6.65 | 10.38 | 50.91 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(4.02) | (3.06) | (2.94) | (2.71) | (10.83) | (6.25) |
EV/FCF |
(3.86) | (2.97) | (2.78) | (2.30) | (10.66) | (6.24) |
Quick Ratio |
1.36 | 1.44 | 2.38 | 4.24 | 6.99 | 4.06 |
Current Ratio |
1.58 | 1.68 | 2.75 | 4.55 | 7.69 | 4.26 |
Net Debt/EBITDA |
(2.16) | (1.27) | (1.06) | (0.17) | 1.11 | (0.06) |
Debt/Assets |
128.32% | 100.73% | 102.32% | 66.76% | 41.41% | 77.11% |
Debt/Equity |
(2.18) | (3.84) | (3.93) | 3.94 | 0.83 | (77.36) |
Asset Turnover |
0.28 | 0.26 | 0.19 | 0.12 | 0.10 | 0.00 |
Operating CF/Net income |
0.74 | 0.68 | 0.81 | 0.99 | 0.75 | 0.76 |
Capex/Depreciation |
(0.03) | (0.78) | (2.06) | (7.91) | (0.99) | (0.01) |
Interest Coverage |
(6.62) | (9.91) | (19.41) | (25.32) | (22.79) | (43.90) |
| 120.90% | 221.75% | 2,881.99% | (143.16%) | (190.33%) | (235.10%) | |
| (49.06%) | (57.91%) | (52.23%) | (46.04%) | (62.99%) | (64.78%) | |
ROIC |
(76.50%) | (89.52%) | (109.91%) | (102.86%) | (137.10%) | (2,059.94%) |
Return on Tangible Assets |
(333.04%) | (267.57%) | (161.03%) | (77.79%) | (63.05%) | (159.97%) |
Average Days of Receivables |
65.93 | 58.82 | 52.48 | 49.32 | 40.64 | 566.22 |
Research and Development Expense of Revenue |
125.44% | 156.64% | 198.00% | 242.53% | 256.70% | 321,960.26% |
Selling, General and Administrative Expense of Revenue |
86.32% | 99.62% | 127.81% | 184.28% | 250.23% | 52,219.23% |
Intangible Assets out of Total Assets |
0.26 | 0.21 | 0.19 | 0.13 | 0.12 | 0.21 |
Share Based Compensation of Revenue |
17.11% | 30.87% | 37.97% | 51.46% | 80.54% | 51,020.51% |
Graham Net Nets |
(1.77) | (1.12) | (0.85) | (0.15) | 0.08 | (0.05) |
Graham Number |
11.20 | 13.73 | 23.25 | 0.00 | 0.00 | 4.39 |
Earnings Yield |
(85.24%) | (92.71%) | (71.24%) | (39.37%) | (11.34%) | (21.12%) |
Free Cash Flow Yield |
(65.28%) | (64.52%) | (60.93%) | (46.01%) | (8.53%) | (16.18%) |
Revenue per Share |
1.29 | 1.95 | 2.65 | 1.83 | 1.18 | 0.00 |
Operating CF per Share |
(1.70) | (3.00) | (6.01) | (7.03) | (5.55) | (6.93) |
Capex per Share |
0.00 | (0.10) | (0.35) | (1.23) | (0.09) | (0.02) |
Free Cash Flow per Share |
(1.70) | (3.10) | (6.36) | (8.26) | (5.63) | (6.95) |
Cash per Share |
1.24 | 2.85 | 5.51 | 9.99 | 11.98 | 6.92 |
Shareholders Equity per Share |
(2.41) | (1.88) | (3.23) | 2.81 | 7.81 | (0.09) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(2.41) | (1.88) | (3.23) | 2.81 | 7.81 | (0.09) |
Free Cash Flow |
(196.37) | (261.08) | (342.38) | (430.24) | (265.01) | (267.38) |
Working Capital |
72.87 | 125.90 | 233.38 | 446.55 | 545.42 | 213.81 |
Capital Expenditures |
(0.31) | (8.35) | (18.76) | (64.24) | (4.10) | (0.70) |
Net Current Asset Value |
(553.59) | (453.47) | (477.39) | (144.79) | 259.35 | (88.78) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.05 | 0.13 | 0.67 | 0.07 | 8.99 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||
Depreciation/Fixed assets |
1.67 | 0.89 | 0.60 | 0.31 | 1.03 | 24.12 |
Cash ROIC |
(41.66%) | (37.76%) | (42.40%) | (34.61%) | (21.44%) | (49.18%) |
Accounts Receivable Turnover |
5.57 | 6.99 | 8.55 | 10.00 | 17.62 | 0.02 |
Accounts Payable Turnover |
1.44 | 1.40 | 1.14 | 1.01 | 0.90 | 0.01 |
Inventory Turnover |
1.75 | 1.44 | 1.29 | 0.81 | 0.31 | 0.00 |
Average Days of Payables |
256.72 | 235.87 | 339.23 | 471.54 | 471.05 | 56,898.29 |
Days of Inventory on Hand |
128.68 | 271.41 | 279.06 | 447.64 | 855.45 | 0.00 |
Average Receivables |
26.69 | 23.54 | 16.73 | 9.54 | 3.15 | 4.17 |
Average Payables |
27.00 | 29.46 | 30.38 | 21.83 | 13.03 | 11.09 |
Average Inventory |
22.20 | 28.62 | 26.80 | 27.29 | 37.52 | — |
Average Assets |
539.19 | 637.58 | 766.58 | 799.40 | 549.89 | 538.97 |
Average Common Equity |
(218.79) | (166.50) | (13.89) | 257.05 | 182.00 | 148.51 |
Columns are period end dates